Journal
ONCOTARGET
Volume 7, Issue 2, Pages 1529-1543Publisher
IMPACT JOURNALS LLC
DOI: 10.18632/oncotarget.6414
Keywords
lysosomal acid lipase; lipid metabolic signaling; myeloid-derived suppressor cells; peroxisome proliferator-activated receptor-gamma; tumor growth and metastasis
Categories
Funding
- National Institutes of Health [CA138759, CA152099, HL087001]
Ask authors/readers for more resources
Lysosomal acid lipase (LAL) is a key enzyme controlling neutral lipid metabolic signaling in myeloid-derived suppressor cells (MDSCs). MDSCs from LAL-deficient (lal(-/-)) mice directly stimulate cancer cell proliferation. PPAR gamma ligand treatment inhibited lal(-/-) MDSCs stimulation of tumor cell growth and metastasis in vivo, and tumor cell proliferation and migration in vitro. In addition, PPAR gamma ligand treatment impaired lal(-/-) MDSCs transendothelial migration, and differentiation from lineage-negative cells. The corrective effects of PPAR gamma ligand on lal(-/-) MDSCs functions were mediated by regulating the mammalian target of rapamycin (mTOR) pathway, and subsequently blocking MDSCs ROS overproduction. Furthermore, in the myeloid-specific dominant-negative PPAR gamma (dnPPAR gamma) overexpression bitransgenic mouse model, tumor growth and metastasis were enhanced, and MDSCs from these mice stimulated tumor cell proliferation and migration. MDSCs with dnPPAR gamma overexpression showed increased transendothelial migration, overactivation of the mTOR pathway, and ROS overproduction. These results indicate that PPAR gamma plays a critical role in neutral lipid metabolic signaling controlled by LAL, which provides a mechanistic basis for clinically targeting MDSCs to reduce the risk of cancer proliferation, growth and metastasis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available